| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2002-12-3738 |
| P953 | full work available at URL | https://ashpublications.org/blood/article-pdf/102/3/964/1689583/h81503000964.pdf |
| http://ashpublications.org/blood/article-pdf/102/3/964/1689583/h81503000964.pdf | ||
| P698 | PubMed publication ID | 12689940 |
| P2093 | author name string | David Boczkowski | |
| Smita Nair | |||
| Johannes Vieweg | |||
| Eli Gilboa | |||
| Mark Dewhirst | |||
| Benjamin Moeller | |||
| P2860 | cites work | CM101, a polysaccharide antitumor agent, does not inhibit wound healing in murine models | Q71693296 |
| Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer | Q72410073 | ||
| Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine | Q73035537 | ||
| Noninvasive visualization of tumors in rodent dorsal skin window chambers | Q73037242 | ||
| Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models | Q73365474 | ||
| Cancer vaccines | Q74539555 | ||
| The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses | Q77180057 | ||
| mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT) | Q77314909 | ||
| Cytotoxic T cell immunity against telomerase reverse transcriptase in humans | Q24676613 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes | Q28139460 | ||
| Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth | Q28578750 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene | Q29547732 | ||
| Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele | Q29547733 | ||
| Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo | Q29614729 | ||
| A survey of telomerase activity in human cancer | Q29614858 | ||
| Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor | Q29619247 | ||
| Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development | Q33633524 | ||
| VEGFs, receptors and angiogenesis | Q33644265 | ||
| The makings of a tumor rejection antigen | Q33748013 | ||
| Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor | Q33832620 | ||
| Tumour vasculature as a target for anticancer therapy. | Q33920565 | ||
| New paradigms for the treatment of cancer: the role of anti-angiogenesis agents | Q33922875 | ||
| Anti-angiogenic agents: clinical trial design and therapies in development | Q34013828 | ||
| Progress in human tumour immunology and immunotherapy | Q34253585 | ||
| Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. | Q35823939 | ||
| Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"? | Q35959154 | ||
| Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2 | Q36223383 | ||
| Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo | Q36367135 | ||
| Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis | Q36369761 | ||
| A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth | Q40692331 | ||
| Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells | Q40701084 | ||
| Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. | Q40856900 | ||
| Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. | Q41049213 | ||
| Signaling vascular morphogenesis and maintenance | Q45058276 | ||
| The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target | Q45889563 | ||
| Cancer undefeated. | Q50954075 | ||
| An innate sense of danger | Q56672999 | ||
| Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro | Q56967620 | ||
| A cancer therapy resistant to resistance | Q59070138 | ||
| A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity | Q69737639 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biochemistry | Q7094 |
| cell biology | Q7141 | ||
| immunology | Q101929 | ||
| angiogenesis inhibitor | Q574834 | ||
| immunotherapy | Q1427096 | ||
| cancer immunotherapy | Q2012719 | ||
| proto-oncogene protein | Q66020913 | ||
| P304 | page(s) | 964-971 | |
| P577 | publication date | 2003-04-03 | |
| 2003-04-10 | |||
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Synergy between tumor immunotherapy and antiangiogenic therapy | |
| P478 | volume | 102 |
| Q24548511 | A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth |
| Q36958112 | A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. |
| Q35918770 | A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors |
| Q56967539 | Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses |
| Q35775192 | Adoptive immunotherapy of cancer using activated autologous lymphocytes--current status and new strategies |
| Q37830361 | Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy |
| Q39431474 | Anti-angiogenesis immunotherapy |
| Q35925619 | Antigenic targets for renal cell carcinoma immunotherapy |
| Q36040825 | Antisense therapy for restenosis following percutaneous coronary intervention. |
| Q37096400 | Apoptotic activities in soft tissue sarcoma: immunohistochemical study and their association with tumour characteristics |
| Q34236740 | CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma |
| Q35826417 | Cancer immunotherapy with mRNA-transfected dendritic cells |
| Q48319918 | Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. |
| Q34880734 | Characterization of the ribonuclease activity on the skin surface |
| Q89532702 | Checkpoint inhibitor immunotherapy in kidney cancer |
| Q36388501 | Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo |
| Q34093354 | Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model |
| Q37777379 | Concepts and Ways to Amplify the Antitumor Immune Response |
| Q61882108 | Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes |
| Q36448084 | Current state and perspectives of dendritic cell vaccination in cancer immunotherapy |
| Q40421485 | Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy |
| Q55241239 | DOX/IL-2/IFN-γ co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment. |
| Q38124437 | Deciphering and reversing tumor immune suppression. |
| Q46598910 | Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. |
| Q39842438 | Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy |
| Q79967042 | Dendritic cells in cancer immunotherapy |
| Q52094690 | Dendritic cells: immunobiology and cancer immunotherapy. |
| Q36569004 | Effects of the tumor microenvironment on the efficacy of tumor immunotherapy. |
| Q38931269 | Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). |
| Q41062063 | Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma |
| Q40019570 | Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment |
| Q45881522 | Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination. |
| Q39637966 | Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway |
| Q36589874 | Future directions for vaccine-based therapies |
| Q34245416 | Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice |
| Q42352666 | Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts. |
| Q42144023 | Hypoxia promotes tumor growth in linking angiogenesis to immune escape |
| Q40006095 | IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers |
| Q36593747 | Immune resistance orchestrated by the tumor microenvironment |
| Q34901858 | Immunization with synthetic VEGF peptides in ovarian cancer |
| Q34558393 | Immunologic targeting of FOXP3 in inflammatory breast cancer cells. |
| Q49592831 | Immunotherapeutic Targeting of Tumor-Associated Blood Vessels |
| Q37159509 | Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma |
| Q36239661 | Immunotherapy for gynaecological malignancies. |
| Q36133140 | Immunotherapy for pancreatic cancer - science driving clinical progress |
| Q37086013 | Immunotherapy opportunities in ovarian cancer. |
| Q33698116 | Inhibition of Melanoma Growth by Subcutaneous Administration of hTERTC27 Viral Cocktail in C57BL/6 Mice |
| Q44352273 | Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. |
| Q89306241 | Inhibitors of Angiogenesis |
| Q30429380 | Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma |
| Q34797653 | Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer |
| Q39024097 | Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity |
| Q35753931 | Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine |
| Q35842616 | Messenger RNA-based vaccines |
| Q35988815 | Modulation of antitumor responses by dendritic cells |
| Q35838744 | New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers |
| Q36116250 | Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy |
| Q36328010 | Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer |
| Q33982878 | Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions |
| Q36111911 | Regulators of apoptosis: suitable targets for immune therapy of cancer |
| Q41998269 | Relationship of angiogenic and apoptotic activities in soft-tissue sarcoma. |
| Q89509390 | Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready 'N Able to Improve Clinical Outcome? |
| Q53717620 | Robust CD4+ and CD8+ T cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag. |
| Q42321216 | Selective modification of antigen-specific T cells by RNA electroporation |
| Q36445546 | Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination |
| Q36555524 | The determinants of tumour immunogenicity |
| Q80038678 | The promise of cancer vaccines |
| Q37598949 | Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses |
| Q35941603 | Tumor-host immune interactions and dendritic cell dysfunction |
| Q37729243 | Tumour escape mechanisms and their therapeutic implications in combination tumour therapy |
| Q43196387 | Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells |
| Q36216702 | Vaccination and malignant disease: promising therapeutic approach. |
| Q34704905 | Vaccines targeting the neovasculature of tumors |
| Q35740182 | Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice |
| Q36764907 | Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. |
Search more.